A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer

LESSONS LEARNED. A shortened infusion of ramucirumab (from 60 to 20 minutes) was safe and feasible without infusion‐related reactions. Twenty‐minute infusions of ramucirumab can be an option for patients with no infusion‐related reactions during the first 60‐minute treatment. BACKGROUND. Ramucirumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Naoya, Mitani, Seiichiro, Taniguchi, Hiroya, Narita, Yukiya, Kato, Kyoko, Masuishi, Toshiki, Kadowaki, Shigenori, Onishi, Sachiyo, Tajika, Masahiro, Takahashi, Shinji, Shimomura, Kazuhiro, Takahata, Chihoko, Hotta, Eri, Kobara, Makiko, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369950/
https://www.ncbi.nlm.nih.gov/pubmed/30305415
http://dx.doi.org/10.1634/theoncologist.2018-0580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369950/
https://www.ncbi.nlm.nih.gov/pubmed/30305415
http://dx.doi.org/10.1634/theoncologist.2018-0580

Ejemplares similares